Skip to content
LACOG - Latin American Cooperative Oncology Group· @LACOG_group · X·· 13 hours agoScore70

DESTINY-BREAST05

Body

On October 23, LACOG investigator Dr. Carlos H. Barrios presented health-related quality-of-life results and patient-reported outcomes from DESTINY-Breast05 at ESMO Congress 2026 in Madrid.

#LACOG #ESMO2026

7 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
539ROmatched by Rapid oral: Breast cancer, early stage

Patient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)

https://esmocongress.esmo.org

Source: LACOG - Latin American Cooperative Oncology Group · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org